Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck

Infusion Sclerotherapy of Microcystic Lymphatic Malformation: Clinico-Radiological Mid-Term Results

“…Bleomycin was introduced for LM sclerotherapy in very early trials (24). However, it may cause fatal complication such as pulmonary interstitial fibrosis or hypersensitivity (25,26). Among the cases in this study, no fatal complications developed after infusion sclerotherapy using OK-432.…”

The role of intralesional Pingyangmycin in the treatment of venous malformation of facial and maxillary region

“…The most feared complication of the use of Bleomycin is pulmonary fibrosis when it is administered during cancer therapy. The risk of this toxicity is felt to be minimal when, as suggested by Sung et al, that the dose per treatment be kept under 1 mg/kg per session and no more frequently than an interval of 2 weeks, with the total dose limited to 5 mg/kg [9]. We adhered to the guidelines and injected the solution of Pingyangmycin keeping the maximum dose <0.5 mg/kg at an interval of no less than 3 weeks.…”

Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck

“…The most feared complication of the use of this drug is pulmonary fibrosis reported when it is administered during cancer therapy. For sclerotherapy in cystic hygroma Sung et al suggested the dose of less than 1 mg/kg at an interval of not less than 2 weeks, with the total dose limited to 5 mg/kg [15]. We used similar regime and injected the solution in concentration of 1 mg/ml for larger lesions and 2 mg/ml for smaller lesions with the maximum dose limited to less than 6 mg/kg.…”